Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial
Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial
Patients with untreated clinical stage II breast cancer are eligible. An excisional biopsy of
 the primary tumor is acceptable, but without definitive local therapy or prior chemotherapy.
 Histologic confirmation of invasive carcinoma is required. Patients are prospectively
 randomized to receive five 21-day cycles of dose-intense (5-fluorouracil, adriamycin,
 leucovorin, cytoxan, granuloctye-colony stimulating factor [FLAC/G-CSF]) chemotherapy either
 before (preoperative) or after (postoperative) local therapy. Chemotherapy is given as an
 outpatient. For patients receiving preoperative chemotherapy, local therapy (modified radical
 mastectomy, or breast segmentectomy/axillary dissection/breast radiotherapy according to
 patient preference) is performed 3-4 weeks after last chemotherapy. For patients receiving
 postoperative chemotherapy, chemotherapy will begin 2-3 weeks after local therapy. Immediate
 reconstruction for mastectomy is acceptable. Upon completion of local therapy and
 chemotherapy in either treatment group, all estrogen receptor positive patients receive
 tamoxifen for 5 years. Follow-up consists of history and physical examination each 3 months
 for first 3 years, each six months for years 4 and 5, and yearly thereafter. Mammogram, bone
 scan, chest x-ray and blood work are performed yearly.
A prospective randomized trial evaluating the effect of preoperative dose intense
 chemotherapy (FLAC/G-CSF) on axillary lymph node metastases in women with clinical stage II
 (T1N1, T2N0, T2N1) breast cancer. Patients will be randomized to receive 5 cycles of
 combination chemotherapy (5-FU, adriamycin, leucovorin, cytoxan, G-CSF) either as initial
 therapy (preoperative) or postoperatively after local therapy (modified radical mastectomy or
 lumpectomy/axillary lymph node dissection/whole breast radiotherapy). Each chemotherapy cycle
 will be 21 days. At the time of local therapy the incidence of axillary metastases in the
 axillary dissection specimen will be determined and compared in the preoperative chemotherapy
 vs. postoperative chemotherapy treatment groups.
INCLUSION CRITERIA

 Women of any age with clinical stage II breast cancer who met the following criteria:

 Patients with stage II breast cancer will include primary tumor less than or equal to 5 cm
 in size with axillary lymph nodes which are clinically ([N0 or N1] [T1N1, T2N0, T2N1]).

 Patients will be staged according to the 1986 AJCC TMM classification.

 Patients with bilateral breast cancer will be eligible provided at least one tumor is
 invasive and classified as stage I or II, and neither breast is stage III.

 Histologic sections of the breast tumor must be classified as an invasive primary breast
 neoplasm of epithelial origin.

 Patients must be geographically accessible for follow-up and willing to return for the
 follow-up at the NCI.

 Patients must be mentally competent to understand and give informed consent for the
 protocol.

 Estrogen receptor (ER) status can include ER positive, negative, or unknown.

 Patients with prior cancers may be eligible as long as they have received curative therapy
 and have had no evidence of recurrence for greater than or equal to 10 years.

 EXCLUSION CRITERIA

 Patients will be excluded from this protocol for the following reasons:

 Advanced local disease or distant metastases (stage III or IV).

 Previous therapy to the breast other than excisional biopsy.

 Pregnancy.

 Unwillingness to use birth control during chemotherapy.

 Chronic disease such as heart, lung, liver, kidney, blood or metabolic disorders which may
 render the patient a poor risk for surgery or chemotherapy. Specifically, liver function -
 SGOT, SGPT, alkaline phosphatase and total bilirubin should be less than 1.5 x the upper
 limits of normal. Renal function - creatinine should be less than 1.7 and/or creatinine
 clearance should be greater than 45 ml/min. If there is any history of cardiac disease,
 patients must have a normal ejection fraction on MUGA scan and no angina.